Skip to content

A clinical trial to compare the side effects of two drugs, cetirizine and levocetirizine, in normal human subjects.

Effects of second-generation antihistamines on cognitive and psychomotor function in healthy subjects: A double-blind, crossover, placebo-controlled study.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2009/091/000024
Enrollment
Unknown
Registered
2009-04-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Tab. Cetirizine: 10 mg single dose Intervention2: Tab. Levocetirizine: 5 mg Single Dose Control Intervention1: Tab. Promethazine: 25 mg single dose Control Intervention2: Placebo: One t

Sponsors

Dr. B. Gitanjali
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. 18-40 years of age 2. Either sex

Exclusion criteria

Exclusion criteria: 1. Subjects on concomitant medications 2. Chronic smokers and alcoholics 3. Subjects with known sleeping disturbances and altered circadian rhythm 4. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
1. Psychometrics using a computerized psychomotor testing instrument, consisting of a battery of tests. The tests are as follows:  Finger tapping test  Simple reaction time  Choice reaction time  Choice discrimination test  Digit picture substitution test  Digit symbol substitution test  Digit letter substitution test  Card sorting test  Digit vigilance test  Numeric working memory test  Immediate picture recall test 2. Sedation using Line Analogue Rating Scales for sedation (LARS) (LARS is employed as a measure of the subjective effects of psychoactive drugs) Timepoint: Pretreatment baseline measurements of the above parameters will be done. Following administration of the drug, subjects will be required to perform a series of tests of cognitive function and psychomotor performance at 1, 3, 6 and 12 hours post dose. A washout period of 7 days will be given between the administrations of drugs. Subjective evaluation of sedation will be done using LARS.

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr. Shahid Akhtar

MD Postgraduate, Department of Pharmacology, JIPMER, Pondicherry

satyamveshi@gmail.com(0413) 2272381 ext 3302

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026